Published online before print February 3, 2005, doi: 10.1161/01.ATV.0000157933.19424.b7
© 2005 American Heart Association, Inc.
Atherosclerosis & Lipoproteins |
Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
The EPIC-Norfolk Prospective Population Study
From the Departments of Cardiology (S.M.B.) and Vascular Medicine (T.T.K., J.J.P.K.), Academic Medical Center, Amsterdam, The Netherlands; Medical Research Council Epidemiology Unit (N.J.W.), Cambridge, the Department of Public Health and Primary Care (R.L., N.E.D., M.S.S., K.T.K.), Institute of Public Health, University of Cambridge, and the Medical Research Council Dunn Nutrition Unit (S.A.B.), Cambridge, United Kingdom; and the Department of Cardiology (J.W.J.), Leiden University Medical Center, Leiden and Sanquin Research at the CLB and Department of Clinical Chemistry (C.E.H.), VU Medical Center, Amsterdam, The Netherlands.
Correspondence to Kay-Tee Khaw, Clinical Gerontology Unit, Box 251 Addenbrooke’s Hospital, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QQ United Kingdom. E-mail kk101{at}medschl.cam.ac.uk
Objectives— To study the prospective relationship between serum levels of type II secretory phospholipase A2 (sPLA2) and the risk of future coronary artery disease (CAD) in apparently healthy men and women.
Methods and Results— We conducted a prospective nested case-control study among apparently healthy men and women aged 45 to 79 years. Cases (n=1105) were people in whom fatal or nonfatal CAD developed during follow-up. Controls (n=2209) were matched by age, sex, and enrollment time. sPLA2 levels were significantly higher in cases than controls (9.5 ng/mL; interquartile range [IQR], 6.4 to 14.8 versus 8.3 ng/mL; IQR, 5.8 to 12.6; P<0.0001). sPLA2 plasma levels significantly correlated with age, body mass index, systolic blood pressure, high-density lipoprotein (HDL) cholesterol levels, and C-reactive protein (CRP) levels. Taking into account matching for sex and age and adjusting for body mass index, smoking, diabetes, systolic blood pressure, low-density lipoprotein cholesterol, HDL cholesterol, and CRP levels, the risk of future CAD was 1.34 (1.02 to 1.71; P=0.02) for people in the highest sPLA2 quartile, compared with those in the lowest (P for linearity=0.03).
Conclusion— Elevated levels of sPLA2 were associated with an increased risk of future CAD in apparently healthy individuals. The magnitude of the association was similar to that observed between CRP and CAD risk, and both associations were independent.
A prospective case-control study was performed to investigate the relationships between levels of secretory phospholipase A2 and the risk of coronary artery disease (CAD). Adjusted for traditional risk factors and C-reactive protein levels, the odds ratio for future CAD was 1.34 for people in the highest quartile (P for linearity=0.03).
Key Words: coronary artery disease • phospholipase A2 • oxidation • inflammation
This article has been cited by other articles:
 |
|
 |
|
  W. Koenig, C. Y. Vossen, Z. Mallat, H. Brenner, J. Benessiano, and D. Rothenbacher Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease Eur. Heart J., November 2, 2009; 30(22): 2742 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Rana, M Cote, J-P Despres, M S Sandhu, P J Talmud, E Ninio, N J Wareham, J J P Kastelein, A H Zwinderman, K-T Khaw, et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study Heart, October 15, 2009; 95(20): 1682 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Rana, B. J. Arsenault, J.-P. Despres, M. Cote, P. J. Talmud, E. Ninio, J. W. Jukema, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women Eur. Heart J., February 18, 2009; (2009) ehp010v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. J. F. Tietge, N. Nijstad, R. Havinga, J. F. W. Baller, F. H. van der Sluijs, V. W. Bloks, T. Gautier, and F. Kuipers Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion J. Lipid Res., March 1, 2008; 49(3): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Keller, S. I. van Leuven, M. C. Meuwese, N. J. Wareham, R. Luben, E. S. Stroes, C. E. Hack, M. Levi, K.-T. Khaw, and S. M. Boekholdt Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2345 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. de Beer and N. R. Webb Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1421 - 1422. [Full Text] [PDF]
|
|
|
|
|
|
B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
|
|
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF]
|
|